Announces variances between interim results and previous forecasts for the fiscal year ending March 2027 and revises the full-year forecast. Interim net sales were 57,489 million yen, operating income was 306 million yen, ordinary income was 689 million yen, and interim net income attributable to owners of parent was -1,566 million yen. Full-year net sales remain 121,800 million yen, while operating income and ordinary income are revised to -4,900 million yen and -4,600 million yen respectively, and net income attributable to owners of parent is revised to -5,100 million yen. The revisions reflect recognition of upfront payments related to a license agreement for a new drug and the impact of special losses.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4569","jir_company_name":"KYORIN Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-11-09","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/4569-20261109-03.pdf","jir_short_summary":"Announces variances between interim results and previous forecasts for the fiscal year ending March 2027 and revises the full-year forecast. Interim net sales were 57,489 million yen, operating income was 306 million yen, ordinary income was 689 million yen, and interim net income attributable to owners of parent was -1,566 million yen. Full-year net sales remain 121,800 million yen, while operating income and ordinary income are revised to -4,900 million yen and -4,600 million yen respectively, and net income attributable to owners of parent is revised to -5,100 million yen. The revisions reflect recognition of upfront payments related to a license agreement for a new drug and the impact of special losses.","jir_summary":"### Overview of Performance\nThis report discloses variances between actual results for the consolidated interim period of the fiscal year ending March 2027 and the interim forecasts published in May 2026, and revises the full-year earnings forecast. Interim net sales fell short of the prior forecast, while operating income and ordinary income exceeded the prior forecast due to unutilized selling expenses and other factors. Conversely, interim net income attributable to owners of parent declined significantly due to special losses and a business transfer loss associated with the succession of the generic drug business. For the full year, revisions incorporate recognition of an upfront payment related to the license agreement for the ARDS treatment candidate \"EB05\" and amounts related to licensed-in products.\n\n### Outlook and Impact\nFull-year earnings forecasts have been revised downward for operating income, ordinary income, and net income. In particular, net income has been revised to -5,100 million yen, which may affect shareholder returns and capital policy. The recognition of upfront license payments and the impact of special losses could influence future revenue structure; we will continue to monitor progress in discussions with counterparties and market conditions.","jir_financial_highlights":"Net Sales: 57,489 (Compared with previous forecast (A) 57,800: -311)\nOperating Income: 306 (Compared with previous forecast (A) -300: +606)\nOrdinary Income: 689 (Compared with previous forecast (A) -100: +789)\nInterim Net Income Attributable to Owners of Parent: -1,566 (Compared with previous forecast (A) 0: -1,566)\nInterim Net Income per Share: -27.26 (Compared with previous forecast (A) 0: -27.26)\nNet Sales (Full Year): 121,800 (Compared with previous forecast (A) 121,800: no change)\nOperating Income (Full Year): -4,900 (Compared with previous forecast (A) 2,000: -4,900)\nOrdinary Income (Full Year): -4,600 (Compared with previous forecast (A) 2,300: -4,600)\nNet Income Attributable to Owners of Parent (Full Year): -5,100 (Compared with previous forecast (A) 1,500: -5,100)","jir_category":"","jir_hashtags":"#KYORINPharmaceutical, #InterimResults, #FullYearRevision, #EB05, #LicenseAgreement","jir_key_figures":"Net Sales: 57,489 million yen (interim)\nOperating Income: 306 million yen (interim)\nOrdinary Income: 689 million yen (interim)","jir_meta_title":"KYORIN Pharmaceutical Co., Ltd. \u2013 Interim Results for FY2027 and Full-Year Revision | EB05 License Payment Included","jir_meta_description":"KYORIN Pharmaceutical Co., Ltd. announces interim results for FY2027 and a revision to the full-year earnings forecast. Interim net sales were 57,489 million yen and operating income was 306 million yen. Revisions reflect upfront payments related to the EB05 license agreement and special losses. Summary of outlook and risks.","jir_og_title":"KYORIN Pharmaceutical Co., Ltd. \u2013 FY2027 Interim Results and Full-Year Revision | EB05","jir_og_description":"Summary of KYORIN Pharmaceutical Co., Ltd.'s FY2027 interim results and full-year revision, highlighting net sales, income figures, and the significance of EB05-related contract payments.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":16660,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-145542","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n